Phosphorylation of KDM3A has also been shown to promote ER binding to the promoter of the oncogene HOXA1 in tamoxifen treated BC cells [57], suggesting that KDM3A plays a role in regulating ER recruitment in endocrine therapy-resistant cells. This evidence concerns the gene KDM3A and breast cancer.